TY - JOUR
T1 - Adjunctive Antidepressant Use in Bipolar Disorder and Its Clinical Correlates
T2 - An Asian Psychotropic Prescription Patterns Consortium Study
AU - Hu, Yi
AU - Chew, Qian Hui
AU - Lin, Shih Ku
AU - Ouyang, Wen Chen
AU - Chen, Chih Ken
AU - Park, Seon Cheol
AU - Jang, Ok Jin
AU - Chee, Kok Yoon
AU - Ding, Kwong Sen
AU - Chong, Jamaline
AU - Zhang, Ling
AU - Li, Keqing
AU - Zhu, Xiaomin
AU - Jatchavala, Chonnakarn
AU - Pariwatcharakul, Pornjira
AU - Kallivayalil, Roy A.
AU - Grover, Sandeep
AU - Avasthi, Ajit
AU - Ansari, Moin
AU - Maramis, Margarita M.
AU - Paing, Phyo Aung
AU - Tan, Chay Hoon
AU - Xiang, Yu Tao
AU - Chong, Mian Yoon
AU - Park, Yong Chon
AU - Kato, Takahiro A.
AU - Shinfuku, Naotaka
AU - Baldessarini, Ross J.
AU - Sim, Kang
N1 - Publisher Copyright:
© 2025 John Wiley & Sons Australia, Ltd.
PY - 2025/6
Y1 - 2025/6
N2 - Introduction: Adjunctive antidepressant (AD) use is prevalent for the treatment of bipolar disorder (BD) in many countries, but there is little information about this practice in Asia. Accordingly, we addressed the prevalence, dosing, and clinical correlates of adjunctive AD use with BD in a large Asian sample. Methods: Patients with BD were recruited across 13 Asian sites (PR China, Hong Kong, India, Indonesia, Japan, South Korea, Malaysia, Myanmar, Pakistan, Singapore, Sri Lanka, Taiwan, and Thailand) for this cross-sectional study. We examined differences between patients with versus without adjunctive AD treatment. Multivariable logistic regression was used to identify factors associated with the use of adjunctive AD. Results: Among a total of 2114 adult participants (47.7% men; age 42.4 years [CI: 41.8–43.0]; BMI 25.0 kg/m2 [24.8–25.2]), the prevalence of AD use averaged 19.8% [18.1–21.6], at a mean imipramine-equivalent dose of 113 [110–116] mg/day. Adjunctive AD use was associated with factors including older age, outpatient status, more depression, suicidal behavior, rapid cycling, and lower doses of MS and antipsychotics (APs). Discussion: Usage of AD treatment for BD in Asia was less than half that reported in Western samples. Such use of AD treatment appeared to be well tolerated but underscores the need for close clinical follow-up to avoid risks of excessive elevation of mood or behavior.
AB - Introduction: Adjunctive antidepressant (AD) use is prevalent for the treatment of bipolar disorder (BD) in many countries, but there is little information about this practice in Asia. Accordingly, we addressed the prevalence, dosing, and clinical correlates of adjunctive AD use with BD in a large Asian sample. Methods: Patients with BD were recruited across 13 Asian sites (PR China, Hong Kong, India, Indonesia, Japan, South Korea, Malaysia, Myanmar, Pakistan, Singapore, Sri Lanka, Taiwan, and Thailand) for this cross-sectional study. We examined differences between patients with versus without adjunctive AD treatment. Multivariable logistic regression was used to identify factors associated with the use of adjunctive AD. Results: Among a total of 2114 adult participants (47.7% men; age 42.4 years [CI: 41.8–43.0]; BMI 25.0 kg/m2 [24.8–25.2]), the prevalence of AD use averaged 19.8% [18.1–21.6], at a mean imipramine-equivalent dose of 113 [110–116] mg/day. Adjunctive AD use was associated with factors including older age, outpatient status, more depression, suicidal behavior, rapid cycling, and lower doses of MS and antipsychotics (APs). Discussion: Usage of AD treatment for BD in Asia was less than half that reported in Western samples. Such use of AD treatment appeared to be well tolerated but underscores the need for close clinical follow-up to avoid risks of excessive elevation of mood or behavior.
KW - Asia
KW - antidepressants
KW - bipolar disorder
KW - doses
KW - prescription rates
UR - https://www.scopus.com/pages/publications/105007618885
U2 - 10.1111/appy.70004
DO - 10.1111/appy.70004
M3 - 文章
AN - SCOPUS:105007618885
SN - 1758-5864
VL - 17
JO - Asia-Pacific Psychiatry
JF - Asia-Pacific Psychiatry
IS - 2
M1 - e70004
ER -